Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Adaptimmune Therapeutics PLC (ADAPY : OTC)

• Company Description    Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. Number of Employees: 506

• Price / Volume Information    Yesterday's Closing Price: $0.03 Daily Weekly Monthly 20 Day Moving Average: 2,204,947 shares Shares Outstanding: 265.05 (millions) Market Capitalization: $6.89 (millions) Beta: 2.44 52 Week High: $0.69 52 Week Low: $0.03 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -43.48% -43.38% 12 Week -88.19% -88.38% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 JUBILEE AVENUE MILTON PARK - ABINGDON,X0 OX14 4RX GBR ph: 44-12-3543-0000 fax: 44-12-3543-0001 ir@adaptimmune.com http://www.adaptimmune.com

• General Corporate Information    Officers Adrian Rawcliffe - Chief Executive Officer and Director David M. Mott - Chairman of the Board of Director William Bertrand - Chief Operating Officer Gavin Wood - Chief Financial Officer Andrew Allen - Director Peer Information Adaptimmune Therapeutics PLC (CORR.) Adaptimmune Therapeutics PLC (RSPI) Adaptimmune Therapeutics PLC (CGXP) Adaptimmune Therapeutics PLC (BGEN) Adaptimmune Therapeutics PLC (GTBP) Adaptimmune Therapeutics PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00653A107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 03/23/26 Share - Related Items Shares Outstanding: 265.05 Most Recent Split Date: (:1) Beta: 2.44 Market Capitalization: $6.89 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/23/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 0.11 EPS Growth vs. Year Ago Period: -140.74% vs. Previous Quarter: 38.89% Sales Growth vs. Year Ago Period: -89.33% vs. Previous Quarter: 87.74% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - - 06/30/25 - -75.83 Current Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - 1.52 Quick Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - 1.29 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - -248.20 Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - -260.82 Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - -255.12 Book Value 12/31/25 - - 09/30/25 - - 06/30/25 - -0.27 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - 0.43 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©